Latest News
Weekly News Roundup | 24 August 2026
Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...
Latest News
NHS Golden Jubilee First Scottish Hospital to Adopt Steriwave
NHS Golden Jubilee Becomes First Scottish Hospital to Adopt Light-Activated Infection Prevention Technology to Prevent Surgical Site Infections GLASGOW — Scotland’s flagship orthopaedic hospital, NHS Golden Jubilee, has become the first in the country to adopt an...
Receptor.AI and Sethera Partner on AI-Guided Peptide Drug Discovery
Receptor.AI and Sethera Therapeutics Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines Collaboration combines Sethera's proprietary enzymatic polymacrocyclisation and trillion-scale encoded screening with Receptor.AI's physics-based...
Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon
Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...
Ziltivekimab ZEUS Trial: What the Null Result Means
The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026
The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Why AI Alone Cannot Solve Healthcare’s Data Fragmentation Problem
Artificial intelligence is transforming healthcare at a remarkable pace. From clinical documentation and predictive analytics to patient engagement and operational automation, AI is being positioned as a powerful force for improving how care is delivered. But there is...
Without Better Benchmarks, AI Drug Discovery Risks Losing Its Way
Artificial intelligence is rapidly reshaping drug discovery. Machine learning models are now used to predict protein structures, design molecules, prioritize targets, and optimize clinical candidates. Investment is surging, publications are multiplying, and claims of...
Burning from the Inside Out: When Strong Values Become Burnout Risks
Is Burnout More Than Workload? Are external pressures the only drivers of burnout, or can self-perception and the manipulation of values also play a role? Burnout, nervous system regulation, and boundaries have become increasingly familiar concepts within...
The Sourcing Channel Moved East
A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...
Parkinson’s Research Field is Approaching a Pivotal Moment
Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...
Base Editing vs CRISPR: What’s the Difference and Why Does it Matter?
In May 2026, a single intravenous infusion reduced LDL cholesterol by up to 62% in patients with a genetic condition that no statin could adequately control. No repeat dosing was required. No serious adverse events were reported. The therapy, VERVE-102, was not a...
Mental Wellness in Your 50s & 60s: Strength and Serenity Ahead
The fifth and sixth decades of life are often portrayed as a period of increased freedom, wisdom, and personal fulfilment. For many individuals, these years bring the anticipation of retirement, the opportunity to travel, deeper family connections through...
The Emerging Health Tech Driving Globalised Healthcare
Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...
PDUFA Date Explained: FDA Drug Approval Deadlines
Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning,...
The Physiology Before Disease: Why Modern Prevention Starts Too Late
Most diseases do not begin the day a diagnosis is made. The body often goes through a series of changes long before medicine has a name for what is happening, and the period between apparent health and confirmed disease is something we still don't fully understand.¹...
Weekly News Roundup | 1 June 2026
Life science news 1 June 2026: FDA approvals, a landmark obesity pill advance and a $10.5 billion Pfizer partnership define a milestone week for pharma and biotech. The week of 24 to 30 May 2026 delivered a string of significant regulatory milestones, high-value...
The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026
The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Why AI Alone Cannot Solve Healthcare’s Data Fragmentation Problem
Artificial intelligence is transforming healthcare at a remarkable pace. From clinical documentation and predictive analytics to patient engagement and operational automation, AI is being positioned as a powerful force for improving how care is delivered. But there is...
Without Better Benchmarks, AI Drug Discovery Risks Losing Its Way
Artificial intelligence is rapidly reshaping drug discovery. Machine learning models are now used to predict protein structures, design molecules, prioritize targets, and optimize clinical candidates. Investment is surging, publications are multiplying, and claims of...
Burning from the Inside Out: When Strong Values Become Burnout Risks
Is Burnout More Than Workload? Are external pressures the only drivers of burnout, or can self-perception and the manipulation of values also play a role? Burnout, nervous system regulation, and boundaries have become increasingly familiar concepts within...
The Sourcing Channel Moved East
A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...
Parkinson’s Research Field is Approaching a Pivotal Moment
Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...
Base Editing vs CRISPR: What’s the Difference and Why Does it Matter?
In May 2026, a single intravenous infusion reduced LDL cholesterol by up to 62% in patients with a genetic condition that no statin could adequately control. No repeat dosing was required. No serious adverse events were reported. The therapy, VERVE-102, was not a...
Mental Wellness in Your 50s & 60s: Strength and Serenity Ahead
The fifth and sixth decades of life are often portrayed as a period of increased freedom, wisdom, and personal fulfilment. For many individuals, these years bring the anticipation of retirement, the opportunity to travel, deeper family connections through...
The Emerging Health Tech Driving Globalised Healthcare
Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...
PDUFA Date Explained: FDA Drug Approval Deadlines
Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning,...
The Physiology Before Disease: Why Modern Prevention Starts Too Late
Most diseases do not begin the day a diagnosis is made. The body often goes through a series of changes long before medicine has a name for what is happening, and the period between apparent health and confirmed disease is something we still don't fully understand.¹...
Weekly News Roundup | 1 June 2026
Life science news 1 June 2026: FDA approvals, a landmark obesity pill advance and a $10.5 billion Pfizer partnership define a milestone week for pharma and biotech. The week of 24 to 30 May 2026 delivered a string of significant regulatory milestones, high-value...
Featured Articles
Further News
The Underestimated Occupational Impact of Pelvic Pain
When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...
Clinical Trials Roundup | 29 May 2026
Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...
AI Will Not Solve Healthcare Inequality. But it Could Lower the Barriers
There’s a lot of discussion right now around AI in healthcare, but most of it feels disconnected from how clinical research actually works day-to-day. A lot of the conversation is centered around automation, replacing people, chatbots, and efficiency. Some of that...
How AI Infrastructure Accelerates the Next Phase of Healthcare Innovation
Artificial intelligence is beginning to reshape healthcare in ways that would have seemed unrealistic just a decade ago. Hospitals are experimenting with tools that can analyze medical images in seconds, help clinicians monitor patients remotely, and even assist with...
The Silent Clock in Your Arteries
The Silent Clock in Your Arteries: Why Vascular Aging Is the Heart Health Crisis We're Missing We are living in an era of extraordinary innovation in heart health. Precision diagnostics. AI-guided therapies. Wearables that track everything from rhythm to recovery. And...
Kailera Therapeutics IPO: A $625M Signal for Biotech
When Kailera Therapeutics priced its initial public offering on 16 April 2026, it did more than raise money. The Kailera Therapeutics IPO set a new benchmark for an industry that had spent the better part of three years in the wilderness. Priced at $625 million, it...
CRISPR-GPT: Stanford’s AI Tool That Automates Gene Editing
A team of researchers from Stanford University School of Medicine, Princeton University, the University of California Berkeley, and Google DeepMind has developed CRISPR-GPT, an AI gene editing system designed to automate and dramatically simplify CRISPR-based gene...
Modernizing Safety: The Predictive Power of In Vitro Toxicology
As global regulators and scientific communities continue to push for more predictive, human-relevant, and ethical approaches to safety testing, in vitro toxicology has emerged as a critical component of modern drug development. Once seen primarily as an early...
Climate-Sensitive Maternal Mental Health Screening
A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....
Biotech’s Missing Ingredient: Execution
Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients. Over the last several years, I have seen strong assets struggle for reasons...
Turning AI Skeptics into AI Advocates Through High-Integrity Data
For years, biopharma has accumulated vast volumes of data. Now, as the industry races toward an AI-driven future, that data must become a true strategic asset. Recent research shows that while 95% of biopharma companies are actively pursuing AI initiatives in...
Burnout is Not a Personal Failure. It is Often a System Design Problem
Burnout has long been viewed as a matter of individual resilience. Individuals are advised to meditate, sleep well, optimise morning routines, cut down on screen time, show gratitude, achieve a good work-life balance, or just be better at managing time. While these...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.